Translational Colorectal Cancer: from Genomics to Therapy
March 4-5, 2021
Course via Web Streaming - Live Webcast to be hosted in Central Daylight Time (CDT)
Conf. ID: D122937
9.50 AMA PRA Category 1 CreditsTM
This activity is intended for all Physicians, Physician Assistants, Nurses, Trainees/Students and Scientists(PhDs).
Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts and so forth.
Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Email: email@example.com. All responses will be forwarded to the Program Chair for consideration.
Currently the two biggest limitations hampering the effective treatment of colorectal cancer are (1) a general lack of effective targeted therapies, and (2) a lack of predictive biomarkers to help oncologist identify which indivdual patients will benefit from either standard chemotherapy or the targeted therapies currently in development. This conference is targeted to basic and translational scientists working on CRC, as well as physicians who treat CRC. It is designed to capture the most up-to-date research on both the molecular working of the colon cancer cell and the clinical treatment of CRC, and present this information in a way so that knowledge from one discipline can inform the other. By doing so it is expected that both CRC scientists and clinicians will leave with increased insight and thus increase ability to perform their functions. It is also expected to increase research collaboration in the CRC community.
- Implement genetic testing of patients and family members to screen for those who are at risk for developing pancreatic cancer and other cancers;
- Evaluate, counsel and treat patients with pancreatic cancer at all stages of disease (locally advanced, resectable, borderline resectable, metastatic);
- Provide a comprehensive understanding of innovative and emerging cancer therapies, inclusive of the side effects, to the cancer patient;
- Apprise fellow clinicians and healthcare providers of emerging paradigms in latest clinical trials and supportive care.
- Panel Discussion
- Question/Answer Sessions
A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this live internet course for a maximum of 9.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Certificates and Attendance Verification Certificates
Certificates awarding AMA PRA Category 1 Credit™ or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME verification form. Upon request, a record of attendance (certificate) will be provided to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.
The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.
Physician Payments Sunshine Act
MD Anderson complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value to any covered recipient under the ACA.
Translational Colorectal Cancer: from Genomics to Therapy will be held on Thursday, March 4, 2021 will begin for registrants at 8:30 a.m., and will adjourn at 12:00 pm on Friday, March 5, 2021.
The virtual conference registration includes access to on-line education materials.
Registration - Fee Exempt
Registration On-line (Below): you may experience intermittent problems with using the Google or FireFox Brower’s, we recommend that you use Internet Explorer Browser when registering on-line.
The Department of Continuing Professional Education reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form. In case of activity cancellation, the liability of the Department of Continuing Professional Education is limited to the registration fee. Continuing Professional Education will refund the full registration fee.
The Department of Continuing Professional Education reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.
For additional information, contact Continuing Professional Education at 713-792-2223 or toll free at 866-849-5866 or via e-mail: firstname.lastname@example.org
Photographing, audio taping and videotaping are prohibited.